Davita clinical research central laboratory expands its services and
technology
Minneapolis--(business wire)--davita clinical research® (dcr®), a provider of clinical research services focused on kidney research as well as a multitude of specialty therapeutic populations, has announced the company’s expansion within its central laboratory. dcr’s central laboratory is focused on providing world-class clinical research in both complex/specialty populations and therapeutic areas, as well as chronic kidney disease (ckd) populations. by year’s end, the lab’s test menu will increase by 43 percent, maintaining the company’s leadership position in advanced renal care while ensuring critical coverage in the areas of oncology, immunology, endocrinology, cardiology and anemia. the testing facility has expanded its technology through the addition of two new testing platforms, the immulite 2000 xpi immunoassay system and the ab sciex qtrap 5500 lc/ms/ms system. other additions include increased specimen management and storage capabilities for both short- and long-term testing. the central laboratory facilitates satisfaction with continuous it advancements, allowing for clean, timely data and ease of customer access to laboratory results. dcr’s commitment to “excellence through innovation” is evident by its continual, selective additions of scientific and operational staff coming from the cro and pharma communities. in addition, dcr recently announced the launch of its biorepository services. the biorepository contains collections of biological material and their pertinent databases that are systemized for the purpose of research. this new, one-of-a-kind, state-of-the-art biorepository dramatically improves the odds of a breakthrough discovery by combining samples meticulously collected from our nationwide network of over 1,700 sites richly annotated with patient-level heath information. “we are proud of our recent investments in equipment and assay development,” stated dcr vice president of commercial development kevin j. goudreau. “these investments will allow us to supply central laboratory services outside of renal care. we will continue to invest heavily in assay development until the breadth of our offering covers virtually all therapeutic indications.” davita and dcr are trademarks or registered trademarks of davita inc. all other trademarks are the property of their respective owners. about davita clinical research (dcr) davita clinical research (dcr) is committed to advancing the knowledge and practice of kidney care. dcr brings unsurpassed knowledge, skill, and expertise to pharmaceutical research, ensuring the success of their clients’ clinical trials. dcr’s clinical expertise ranges from designing the study to preparing and submitting the final report. dcr’s early clinical research unit (phase i-iia) and clinical development network of physicians and investigative sites, health economics and central laboratory are focused on providing world-class clinical research in both complex/specialty populations and therapeutic areas as well as ckd and esrd populations needed to meet clinical goals. to learn more about dcr, visit www.davitaclinicalresearch.com. about davita davita inc. (nyse: dva), a fortune 500® company, is a leading provider of kidney care in the united states, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. davita strives to improve patients’ quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health-management services. as of june 30, 2011, davita operated or provided administrative services at 1,669 dialysis facilities, serving approximately 131,000 patients. davita supports numerous programs dedicated to creating positive, sustainable change in communities around the world. the company’s leadership development initiatives and social responsibility efforts have been recognized by fortune, modern healthcare, newsweek and worldblu. for more information, please visit www.davita.com.
